Veloxis Pharmaceuticals Inc. v. Sun Pharmaceutical Industries Ltd.

Parties and Accused Product at Center of Generic Drug Dispute

This patent infringement action involves plaintiff Veloxis Pharmaceuticals Inc., a commercial-stage specialty pharmaceutical company focused on products for transplant patients, and defendant Sun Pharmaceutical Industries Ltd., a large Indian multinational company that manufactures and sells generic pharmaceutical formulations and active pharmaceutical ingredients (APIs). Veloxis, a US subsidiary of Japan's Asahi Kasei, markets the drug Envarsus XR, a once-daily extended-release tablet formulation of the immunosuppressant tacrolimus, used to prevent organ rejection in kidney transplant patients. The litigation was triggered by Sun Pharma's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Envarsus XR prior to the expiration of Veloxis's patents. This is a standard Hatch-Waxman Act litigation, where a generic drug manufacturer's ANDA filing is considered a technical act of patent infringement that allows the brand-name drug manufacturer to sue before the generic product is launched.

Patent-at-Issue and Procedural Posture

The lawsuit centered on U.S. Patent No. 9,549,918, which covers a stabilized pharmaceutical composition of tacrolimus. Specifically, the patent describes a formulation that includes a stabilizing agent, such as an organic acid, to prevent or reduce the degradation of the active ingredient tacrolimus, thereby ensuring a stable oral dosage form. The case was filed in the U.S. District Court for the District of Delaware, a popular venue for patent litigation, particularly Hatch-Waxman cases, due to its experienced judiciary and well-developed case law in this area. The case was assigned to Judge Maryellen Noreika. The matter was resolved through a settlement agreement just before a bench trial was scheduled to begin in April 2026.

The case is notable as a key defense of a significant product for Veloxis. Envarsus XR is the company's lead product, and its market exclusivity is critical to Veloxis's business, which is focused on the transplant sector. The settlement, which prevents Sun Pharma from launching its generic until May 2028, demonstrates the value of the patent portfolio in protecting the market for this specialty drug. The litigation and its outcome are typical of the high-stakes legal battles between brand-name pharmaceutical companies and generic manufacturers seeking to enter the market, with the District of Delaware frequently serving as the legal battleground for these disputes.

Key Legal Developments and Outcome

This Hatch-Waxman litigation was initiated by Veloxis to block Sun Pharma's attempt to market a generic version of Envarsus XR® (tacrolimus extended-release tablets), a medication used to prevent organ rejection in kidney transplant patients. The case was resolved through a settlement that ensures Veloxis's market exclusivity for an additional period.

Chronological Case History

2024-06-19: Complaint Filed
Veloxis Pharmaceuticals Inc. filed a patent infringement lawsuit against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware (Case No. 1:24-cv-00726). The complaint alleged that Sun's Abbreviated New Drug Application (ANDA) for a generic version of Envarsus XR infringed one or more claims of U.S. Patent No. 9,549,918, titled "Stabilized tacrolimus composition." The action was triggered by the receipt of Sun's Paragraph IV certification notice on May 9, 2024. This filing automatically stayed FDA approval of Sun's ANDA for up to 30 months.

2024-07-22: Answer and Counterclaims Filed
After receiving an extension, Sun Pharma filed its answer to the complaint. Sun denied infringement and asserted counterclaims seeking a declaratory judgment that its proposed generic product does not infringe the '918 patent and that the patent is invalid. While the specific grounds for invalidity (e.g., obviousness, lack of enablement) are not detailed in available public documents, this is a standard defense strategy in ANDA litigation.

2024-08-12: Answer to Counterclaims
Veloxis filed its answer to Sun's counterclaims, denying the allegations of non-infringement and invalidity and maintaining that the '918 patent was valid and infringed.

2025-2026: Discovery and Pre-Trial Proceedings
The case proceeded through the discovery phase. A scheduling order set deadlines for expert reports, with opening reports due by December 5, 2025, and rebuttal and reply reports due in January and February 2026. The docket indicates active litigation during this period, including a motion by Sun to strike the supplemental expert report of one of Veloxis's experts, suggesting the parties were engaged in fact and expert discovery disputes leading up to the planned trial. However, public records do not contain detailed information on substantive pre-trial motions, such as motions for summary judgment, or the outcome of any claim construction (Markman) hearing, which would have been a critical step in defining the scope of the patent claims for the court.

Parallel PTAB Proceedings: None Identified
A search for inter partes review (IPR) or post-grant review (PGR) proceedings before the Patent Trial and Appeal Board (PTAB) did not reveal any petitions filed by Sun Pharmaceutical against U.S. Patent No. 9,549,918. While Sun has been involved in other PTAB proceedings, there is no evidence that this parallel administrative challenge was used as a tactic in this specific case.

2026-04-06: Settlement and Consent Judgment
Days before a bench trial was scheduled to begin, the parties reached a settlement. They filed a stipulation of dismissal, and Judge Maryellen Noreika entered a Consent Judgment. The case was officially terminated on this date.

Outcome and Disposition

The litigation concluded with a settlement agreement favorable to Veloxis. The key terms of the resolution are:

• Generic Entry Date: Sun Pharmaceutical is prohibited from launching its generic version of Envarsus XR in the U.S. until May 2028.
• Dismissal: All claims and counterclaims in the district court litigation were dismissed.
• Consent Judgment: The parties agreed to the entry of a consent judgment which resolved the patent infringement claims.

This outcome averted a costly bench trial and provided Veloxis, a subsidiary of Asahi Kasei Corp., with several years of additional market exclusivity for its key product, Envarsus XR.

Based on a review of available court documents and professional biographies, the following attorneys represent the plaintiff, Veloxis Pharmaceuticals Inc., in this matter.

Lead Counsel

While the initial complaint listing all counsel was not publicly retrieved, attorneys from McDonnell Boehnen Hulbert & Berghoff LLP (MBHB) are consistently involved in Veloxis's patent litigation, indicating their role as lead counsel.

• Name: Paul H. Berghoff

  • Role: Lead Counsel (highly likely)
  • Firm: McDonnell Boehnen Hulbert & Berghoff LLP (Chicago, IL)
  • Relevant Experience: A founding partner of MBHB, Berghoff has over three decades of experience as lead trial counsel in complex pharmaceutical and medical device patent litigation.

• Name: Daniel A. Boehnen

  • Role: Lead Counsel (highly likely)
  • Firm: McDonnell Boehnen Hulbert & Berghoff LLP (Chicago, IL)
  • Relevant Experience: A founding partner of the firm, his practice focuses on trials and appeals in disputed patent matters across a wide range of high-tech industries.

Delaware Counsel

Attorneys from Morris, Nichols, Arsht & Tunnell LLP appear to serve as local counsel in Delaware, a common practice in the district.

• Name: Jeremy A. Tigan

  • Role: Local Counsel
  • Firm: Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE)
  • Relevant Experience: An IP litigation partner whose appearance for Veloxis is confirmed by a signed filing in this case (Case 1:24-cv-00726-UNA, D.I. 3); his practice centers on patent infringement and trade secret disputes in the District of Delaware, with a focus on pharmaceuticals and software.

• Name: Karen Ann Jacobs

  • Role: Local Counsel (likely)
  • Firm: Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE)
  • Relevant Experience: With over 35 years of experience, she focuses on patent infringement litigation in Delaware and has represented numerous pharmaceutical and life sciences companies.

In-house counsel for Veloxis Pharmaceuticals Inc. have not filed a notice of appearance in this case according to the available public records.

Defendant's Counsel of Record

Sun Pharmaceutical Industries Ltd. was represented by attorneys from the intellectual property specialty firm Sterne, Kessler, Goldstein & Fox P.L.L.C., with local counsel from Farnan LLP in Delaware.

• J.C. Rozendaal (Lead Counsel)

  • Firm: Sterne, Kessler, Goldstein & Fox P.L.L.C., Washington, D.C.
  • Note: Rozendaal is a director at Sterne Kessler and chairs the firm's litigation practice, with extensive experience in leading Hatch-Waxman ANDA litigations.

• Michael Joffre (Of Counsel)

  • Firm: Sterne, Kessler, Goldstein & Fox P.L.L.C., Washington, D.C.
  • Note: Joffre is a director at Sterne Kessler and has a background in litigating complex pharmaceutical patent cases, including those involving oral dosage forms.

• William H. Milliken (Of Counsel)

  • Firm: Sterne, Kessler, Goldstein & Fox P.L.L.C., Washington, D.C.
  • Note: Milliken, a director at Sterne Kessler, has significant experience in pharmaceutical patent litigation and has been involved in numerous ANDA cases.

• Brian R. Farnan (Local Counsel)

  • Firm: Farnan LLP, Wilmington, Delaware.
  • Note: Farnan frequently serves as Delaware local counsel in major patent disputes, leveraging his experience with the District of Delaware's local patent rules and judges.

• Michael J. Farnan (Local Counsel)

  • Firm: Farnan LLP, Wilmington, Delaware.
  • Note: Michael Farnan, like his partner Brian, provides local counsel services in a wide array of patent infringement cases filed in the District of Delaware.